Metabolomic profiling of U87MG glioblastoma cells expressing these mutations in IDH1 determined the structural change of the mutated protein results in acquisition of the ability to convert α–ketoglutarate to R(-)-2-hydroxyglutarate (2HG). The gene discussed is IDH1; the disease is glioblastoma.